EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis

Nephron - Experimental Nephrology

Volumn 106, Issue 4, 2007, Pages

  Muto, Yuko ^a   Suzuki, Kokichi ^a   Iida, Hiroyuki ^a   Ishii, Hidemi ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Carboxypeptidase B; EF6265; Fibrinolysis; Renal dysfunction; Thrombin activatable fibrinolysis inhibitor (TAFI); Thrombotic glomerulonephritis

Indexed keywords

7 AMINO 2 [[[2 METHYL 1 (3 PHENYLPROPANOYLAMINO)PROPYL]HYDROXYPHOSPHINOYL]METHYL]HEPTANOIC ACID; ALANINE AMINOTRANSFERASE; ALTEPLASE; CARBOXYPEPTIDASE B; EF 6265; FIBRINOLYTIC AGENT; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HEPARIN; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; NITROGEN; PEPTIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EDEMA; EXPERIMENTAL MODEL; FIBRIN CLOT; FIBRINOLYSIS; GLOMERULONEPHRITIS; HISTOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY EDEMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MICROTHROMBUS; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RENAL PROTECTION; SHORT COURSE THERAPY; STAINING; THROMBOTIC GLOMERULONEPHRITIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URINE VOLUME;

AMINO ACIDS; ANIMALS; CARBOXYPEPTIDASE B; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; GLOMERULONEPHRITIS; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; PHOSPHINIC ACIDS; RATS; RATS, WISTAR; THROMBOSIS;

EID: 34547421328     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104835     Document Type: Article

References (26)

1. Hertig A, Rondeau E: Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J Am Soc Nephrol 2004;15:844-853.
2. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM, Stearns-Kurosawa DJ, Kurosawa S: Inflammation, sepsis, and coagulation. Haematologica 1999;84:254-259.
3. Bauer PR: Microvascular responses to sepsis: clinical significance. Pathophysiology 2002;8:141-148.
4. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-56.
5. Call JT, Deliargyris EN, Sane DC: Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost 2004;30:297-304.
6. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(1 suppl):64S-94S.
7. De Vriese AS: Prevention and treatment of acute renal failure in sepsis. J Am Soc Nephrol 2003;14:792-805.
8. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995;270:14477-14484.
9. Bouma BN, Meijers JC: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003;1:1566-1574.
10. Leurs J, Hendriks D: Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005;94:471-487.
11. Wu C, Dong N, da Cunha V, Martin-McNulty B, Tran K, Nagashima M, Wu Q, Morser J, Wang YX: Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003;90:414-421.
12. Muto Y, Suzuki K, Sato E, Ishii H: Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003;461:181-189.
13. Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S, Ishii H: Enhancement of fibrinolysis by EF6265, a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004;309:607-615.
14. Naruse T, Tsuchida A, Ogawa S, Yano S, Maekawa T: Selective glomerular thrombosis in rats induced by combined injections of nephrotoxic antiserum and lipopolysaccharide. J Lab Clin Med 1985;105:146-156.
15. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, Akatsu H, Campbell W, Okada N, Okada H, Yuzawa Y, Matsuo S: Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002;61:490-501.
16. Hosaka Y, Takahashi Y, Ishii H: Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998;79:371-377.
17. Mosnier LO, Meijers JC, Bouma BN: Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001;85:5-11.
18. Sawada K, Yamamoto H, Matsumoto K, Yago H, Suehiro S, Tahara C, Ishii H, Kazama M, Abe T: Changes in thrombomodulin level in plasma of endotoxin-infused rabbits. Thromb Res 1992;65:199-209.
19. Kume M, Hayashi T, Yuasa H, Tanaka H, Nishioka J, Ido M, Gabazza EC, Kawarada Y, Suzuki K: Bacterial lipopolysaccharide decreases thrombomodulin expression in the sinusoidal endothelial cells of rats - a possible mechanism of intrasinusoidal microthrombus formation and liver dysfunction. J Hepatol 2003;38:9-17.
20. Rijneveld AW, Weijer S, Florquin S, Esmon CT, Meijers JC, Speelman P, Reitsma PH, Ten Cate H, van der Poll T: Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004;103:1702-1709.
21. Aya N, Yoshioka K, Murakami K, Hino S, Okada K, Matsuo O, Maki S: Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J Pathol 1992;166:289-295.
22. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997;185:963-968.
23. Mathieson PW, Thiru S, Peters DK, Oliveira DB: Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis. Int J Exp Pathol 1991;72:679-693.
24. Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest 2005;128:2864-2875.
25. Kawamura T, Okada N, Okada H: Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002;46:225-230.
26. Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH: A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2004;2:54-57.